Compositions and methods for enhancing mood

Abstract

Compositions comprising odd-chain saturated fatty acids, and salts and derivatives thereof, and methods for elevating and / or enhancing mood, reducing anxiety and / or pain, treating depression, treating major depressive disorder, or treating seasonal affective disorder are provided.

Description

[Technical Field]

[0001] (Incorporation by reference to related applications) This application claims priority to U.S. Provisional Application No. 63 / 068,263, filed on 20 August 2020. The aforementioned application is incorporated herein by reference in its entirety and is hereby expressly made part of this Spec.

[0002] (Technical field) Compositions comprising odd-chain saturated fatty acids, salts thereof, and derivatives thereof, as well as methods for raising and / or enhancing mood, reducing anxiety and / or pain, treating depression, treating major depressive disorder, or treating seasonal affective disorder. [Background technology]

[0003] Mood disorders or pain increase the risk of health conditions that can reduce quality of life and lifespan. Individuals suffering from mood disorders or pain are at higher risk of developing a range of conditions, including cardiovascular disease, fatty liver disease, pro-inflammatory conditions, and pro-thrombogenic conditions. Mood disorders and pain have been identified as causative or contributing factors to these conditions, and therefore, treatment of mood disorders and pain has been proposed as a means of treating or preventing these conditions and thereby improving health and quality of life. [Overview of the Initiative]

[0004] Compositions and methods are provided for raising and / or enhancing mood, reducing anxiety and / or pain, treating depression, treating major depressive disorder, or treating seasonal affective disorder. These compositions comprise one or more odd-chain saturated fatty acids, derivatives of odd-chain saturated fatty acids, or salts thereof, which may be administered in combination with other drugs or supplements, or as part of various therapeutic regimens as described herein.

[0005] Accordingly, a generally applicable first embodiment (i.e., independently combinable with any of the embodiments or models identified herein) is provided for a method of treating depression, major depressive disorder, or seasonal affective disorder, which comprises administering to a patient in need an effective amount of a C15:0 fatty acid or a pharmaceutically acceptable salt thereof in a pharmaceutical composition, a dietary supplement, or a food.

[0006] In an embodiment of the first aspect (i.e., which can be independently combined with any aspect or embodiment specified herein), the method is for raising and / or enhancing mood.

[0007] In an embodiment of the first aspect (i.e., which can be independently combined with any aspect or embodiment identified herein), the method is for reducing anxiety.

[0008] In an embodiment of the first aspect (i.e., which can be independently combined with any of the aspects or embodiments specified herein), the method is for reducing pain.

[0009] In an embodiment of the first aspect (i.e., which can be independently combined with any aspect or embodiment specified herein), the method is for treating depression.

[0010] In an embodiment of the first aspect (i.e., which can be independently combined with any aspect or embodiment identified herein), the method is for the treatment of major depressive disorder.

[0011] In an embodiment of the first aspect (i.e., which can be independently combined with any aspect or embodiment identified herein), the method is for treating seasonal affective disorder.

[0012] In one embodiment of the first aspect (i.e., combinable independently of any of the aspects or embodiments identified herein), the serum, plasma, or erythrocyte membrane concentration of C15:0 fatty acid is increased to a concentration greater than 2.2 μM and less than 30 μM.

[0013] In an embodiment of the first aspect (i.e., combinable independently of any of the aspects or embodiments specified herein), the C15:0 fatty acid is pentadecanoic acid.

[0014] In one embodiment of the first aspect (i.e., combinable independently of any of the aspects or embodiments identified herein), the C15:0 fatty acid or a pharmaceutically acceptable salt thereof is provided as a pharmaceutical composition in unit dosage form comprising the C15:0 fatty acid or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

[0015] In one embodiment of the first aspect (i.e., combinable independently of any of the aspects or embodiments specified herein), the unit dosage form comprises 0.01 mg to 10,000 mg of the C15:0 fatty acid or a pharmaceutically acceptable salt thereof.

[0016] In an embodiment of the first aspect (i.e., combinable independently of any of the aspects or embodiments specified herein), the pharmaceutical composition is substantially free of even-chain saturated fatty acids.

[0017] In an embodiment of the first aspect (i.e., combinable independently of any of the aspects or embodiments specified herein), the pharmaceutical composition is substantially free of polyunsaturated fatty acids.

[0018] In one embodiment of the first aspect (i.e., combinable independently of any of the aspects or embodiments identified herein), the C15:0 fatty acid or a pharmaceutically acceptable salt thereof is administered to a patient once a day.

[0019] In an embodiment of the first aspect (i.e., combinable independently with any of the aspects or embodiments identified herein), the patient is a human.

[0020] In an embodiment of the first aspect (i.e., combinable independently with any of the aspects or embodiments identified herein), the patient is a mammal.

[0021] In an embodiment of the first aspect (i.e., combinable independently with any of the aspects or embodiments identified herein), the patient is a domestic animal.

[0022] In an embodiment of the first aspect (i.e., combinable independently with any of the aspects or embodiments specified herein), the domestic animal is a dog or a cat.

[0023] In an embodiment of the first aspect (i.e., combinable independently with any of the aspects or embodiments identified herein), the domestic animal is a cow, a pig, a sheep, a goat, a horse, a chicken, a duck, or a turkey.

[0024] In one embodiment of the first aspect (i.e., can be combined independently with any of the aspects or embodiments identified herein), a C15:0 fatty acid or a pharmaceutically acceptable salt thereof, from 0.1 mg or less to 500 mg or more, for example, from 0.2 mg to 20 mg, from 2.5 mg to 50 mg, for example, from 1.0 to 5.0 mg, for example, from 20 to 500 mg, for example, from 20 to 200 mg, for example, 100 mg, is administered to the patient per day per kg of body weight. In some embodiments, the effective amount of the C15:0 fatty acid or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is 0.2 - 20 mg / kg body weight.

[0025] In a generally applicable second embodiment (i.e., independently combinable with any of the embodiments or models identified herein), a composition is provided comprising a C15:0 fatty acid or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, for mood enhancement and / or enhancement, for anxiety and / or pain reduction, for the treatment of depression, for the treatment of major depressive disorder, or for the treatment of seasonal affective disorder.

[0026] In embodiments of the second aspect (i.e., those that can be combined independently with any of the aspects or embodiments specified herein), the composition is a pharmaceutical composition in unit dosage form.

[0027] In an embodiment of the second aspect (i.e., which can be combined independently with any of the aspects or embodiments specified herein), the composition is a dietary supplement.

[0028] In embodiments of the second embodiment (i.e., which can be combined independently with any of the embodiments or models specified herein), the dietary supplement is in the form of a single dosage form.

[0029] In embodiments of the second aspect (i.e., those that can be combined independently with any of the aspects or embodiments specified herein), the dietary supplement is in a form adapted to be combined with or added to a food, beverage, or other foodstuff.

[0030] In embodiments of the second aspect (i.e., those that can be combined independently with any of the aspects or embodiments specified herein), the composition is a food or other foodstuff.

[0031] In embodiments of the second aspect (i.e., which can be combined independently with any of the aspects or embodiments specified herein), the composition is for mood enhancement and / or enhancement.

[0032] In embodiments of the second aspect (i.e., those that can be independently combined with any of the aspects or embodiments identified herein), the composition is intended to reduce anxiety.

[0033] In embodiments of the second aspect (i.e., which can be combined independently with any of the aspects or embodiments specified herein), the composition is for reducing pain.

[0034] In an embodiment of the second aspect (i.e., which can be combined independently with any of the aspects or embodiments specified herein), the composition is for the treatment of depression.

[0035] In embodiments of the second aspect (i.e., which can be independently combined with any of the aspects or embodiments specified herein), the composition is for the treatment of major depressive disorder.

[0036] In an embodiment of the second aspect (i.e., which can be independently combined with any of the aspects or embodiments specified herein), the composition is for the treatment of seasonal affective disorder.

[0037] In one embodiment of a second aspect (i.e., which can be combined independently with any of the aspects or embodiments identified herein), the composition is adapted to increase the serum, plasma, or erythrocyte membrane concentration of C15:0 fatty acid or a pharmaceutically acceptable salt thereof to a concentration greater than 2.2 μM and less than 30 μM.

[0038] In one embodiment of a second aspect (i.e., which can be combined independently with any of the aspects or embodiments identified herein), the C15:0 fatty acid or a pharmaceutically acceptable salt thereof is pentadecanoic acid.

[0039] In one embodiment of a second aspect (i.e., which can be combined independently with any of the aspects or embodiments specified herein), the unit dosage form comprises 0.01 mg to 10,000 mg of a C15:0 fatty acid or a pharmaceutically acceptable salt thereof.

[0040] In embodiments of the second aspect (i.e., those that can be combined independently with any of the aspects or embodiments specified herein), the pharmaceutical composition is substantially free of even-chain saturated fatty acids.

[0041] In embodiments of the second aspect (i.e., those that can be independently combined with any of the aspects or embodiments specified herein), the pharmaceutical composition is substantially free of polyunsaturated fatty acids.

[0042] In one embodiment of a second aspect (i.e., which can be combined independently with any of the aspects or embodiments identified herein), the composition is adapted to administer to a patient in need a C15:0 fatty acid or a pharmaceutically acceptable salt thereof in an amount of 1 mg or less to 500 mg or more per kg of body weight, for example, 0.2 mg to 20 mg, 2.5 mg to 50 mg, for example, 1.0 to 5.0 mg, for example, 20 to 500 mg, for example, 20 to 200 mg, for example, 100 mg. In some embodiments, the effective amount of C15:0 fatty acid or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is 0.2 to 20 mg / kg body weight.

[0043] In embodiments of the second embodiment (i.e., which can be combined independently with any of the embodiments or models specified herein), the unit dosage form is adapted for once-daily administration to a patient.

[0044] In embodiments of the second aspect (i.e., those that can be independently combined with any of the aspects or embodiments identified herein), the patient is a human being.

[0045] In embodiments of the second aspect (i.e., those that can be independently combined with any of the aspects or embodiments identified herein), the patient is a mammal.

[0046] In embodiments of the second aspect (i.e., those that can be independently combined with any of the aspects or embodiments identified herein), the patient is livestock.

[0047] In embodiments of the second aspect (i.e., those that can be combined independently with any of the aspects or embodiments specified herein), the livestock is a dog or a cat.

[0048] In embodiments of the second aspect (i.e., those that can be independently combined with any of the aspects or embodiments identified herein), the livestock are cattle, pigs, sheep, goats, horses, turkeys, ducks, or chickens.

[0049] In a generally applicable third embodiment (i.e., independently combinable with any of the embodiments or models identified herein), the use of a composition is provided for raising and / or enhancing mood, reducing anxiety and / or pain, treating depression, treating major depressive disorder, or treating seasonal affective disorder, the composition comprising a C15:0 fatty acid or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

[0050] In embodiments of the third aspect (i.e., those that can be combined independently with any of the aspects or embodiments specified herein), the use is for mood enhancement and / or enrichment.

[0051] In embodiments of the third aspect (i.e., which can be independently combined with any of the aspects or embodiments identified herein), the use is for reducing anxiety and / or pain.

[0052] In an embodiment of the third aspect (i.e., which can be independently combined with any of the aspects or embodiments identified herein), the use is for the treatment of depression.

[0053] In embodiments of the third aspect (i.e., those that can be independently combined with any of the aspects or embodiments identified herein), the use is for major depressive disorder.

[0054] In embodiments of the third aspect (i.e., which can be combined independently with any aspect or embodiment specified herein), the use is for the treatment of seasonal affective disorder.

[0055] In one embodiment of a third aspect (i.e., which can be combined independently with any of the aspects or embodiments identified herein), the serum, plasma, or erythrocyte membrane concentration of C15:0 fatty acid is increased to a concentration greater than 2.2 μM and less than 30 μM.

[0056] In embodiments of the third aspect (i.e., those that can be combined independently with any of the aspects or embodiments specified herein), the C15:0 fatty acid is pentadecanoic acid.

[0057] In one embodiment of a third aspect (i.e., which can be combined independently with any of the aspects or embodiments identified herein), a C15:0 fatty acid or a pharmaceutically acceptable salt thereof is provided as a pharmaceutical composition in a unit dosage form comprising a C15:0 fatty acid or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

[0058] In one embodiment of a third aspect (i.e., which can be combined independently with any of the aspects or embodiments specified herein), the unit dosage form comprises 0.01 mg to 10,000 mg of C15:0 fatty acid or a pharmaceutically acceptable salt thereof.

[0059] In embodiments of the third aspect (i.e., those that can be combined independently with any of the aspects or embodiments specified herein), the pharmaceutical composition is substantially free of even-chain saturated fatty acids.

[0060] In embodiments of the third aspect (i.e., those that can be combined independently with any of the aspects or embodiments specified herein), the pharmaceutical composition is substantially free of polyunsaturated fatty acids.

[0061] In one embodiment of a third aspect (i.e., which can be combined independently with any of the aspects or embodiments identified herein), a C15:0 fatty acid or a pharmaceutically acceptable salt thereof is administered to the patient once daily.

[0062] In embodiments of the third aspect (i.e., those that can be independently combined with any of the aspects or embodiments identified herein), the patient is a human being.

[0063] In embodiments of the third aspect (i.e., those that can be combined independently with any of the aspects or embodiments identified herein), the patient is a mammal.

[0064] In an embodiment of the third aspect (i.e., one that can be independently combined with any of the aspects or embodiments identified herein), the patient is livestock.

[0065] In an embodiment of the third aspect (i.e., one that can be independently combined with any of the aspects or embodiments identified herein), the livestock is a dog or a cat.

[0066] In embodiments of the third aspect (i.e., those that can be independently combined with any of the aspects or embodiments identified herein), the livestock are cattle, pigs, sheep, goats, horses, turkeys, ducks, or chickens.

[0067] In one embodiment of a third aspect (i.e., which can be independently combined with any of the aspects or embodiments identified herein), C15:0 fatty acids or pharmaceutically acceptable salts thereof are administered to a patient per kg of body weight per day in amounts ranging from 1 mg or less to 500 mg or more, for example, 0.2 mg to 20 mg, 2.5 mg to 50 mg, for example, 1.0 to 5.0 mg, for example, 20 to 500 mg, for example, 20 to 200 mg, for example, 100 mg. In some embodiments, the effective amount of C15:0 fatty acids or pharmaceutically acceptable salts thereof in the pharmaceutical composition is 0.2 to 20 mg / kg body weight.

[0068] In one embodiment of a third aspect (i.e., which can be combined independently with any of the aspects or embodiments identified herein), a C15:0 fatty acid or a pharmaceutically acceptable salt thereof is administered as a food component.

[0069] Any feature of the embodiments of the first to sixth embodiments is applicable to all embodiments and forms specified herein. Furthermore, any feature of the embodiments of the first to sixth embodiments can be combined in part or in whole independently with other embodiments described herein, for example, one, two, or three or more embodiments may be combined in whole or in part. Furthermore, any feature of the embodiments of the first to sixth embodiments may be optionally made for other embodiments or forms. Any embodiment or form of a method or use can be carried out using a composition of another embodiment or form, and any embodiment or form of a composition can be adapted to a method or use of another embodiment or form. [Brief explanation of the drawing]

[0070] [Figure 1] Figure 1 shows a bar graph of the target CB1 and CB2 agonist activity of pentadecanoic acid at increasing concentrations.

[0071] [Figure 2]Figure 2 shows line graphs of the phenotypic profiles of pentadecanoic acid and bupropion HCl. Detailed explanation

[0072] Compositions and methods are provided for raising and / or enhancing mood, reducing anxiety and / or pain, treating depression, treating major depressive disorder, or treating seasonal affective disorder. These compositions comprise one or more odd-chain saturated fatty acids, derivatives of odd-chain saturated fatty acids, or salts thereof, which may be administered in combination with other drugs or supplements, or as part of various therapeutic regimens as described herein.

[0073] (definition) The term “alcohol,” as used herein, is a broad term and should be given to those skilled in the art its ordinary and conventional meaning (not limited to any special or customized meaning), and refers to, but is not limited to, any compound described herein that incorporates one or more hydroxyl groups, or is substituted or functionalized to contain one or more hydroxyl groups.

[0074] As used herein, the term “derivative” is a broad term and should be given its usual customary meaning to those skilled in the art (not limited to any special or customized meaning), and refers to, but is not limited to, any compound described herein that incorporates one or more derivative groups, or is substituted or functionalized to contain one or more derivative groups. Examples of derivatives include, but are not limited to, esters, amides, anhydrides, acid halides, thioesters, phosphates, triphosphates, and β-sulfenyl derivatives.

[0075] The term "hydrocarbon," as used herein, is a broad term and should be given its usual and customary meaning to those skilled in the art (not limited to any special or customized meaning), referring to, but not limited to, any part containing only carbon and hydrogen atoms. Functionalized or substituted hydrocarbon parts have one or more substituents as described elsewhere herein.

[0076] As used herein, the term "lipid" is a broad term and should be given its usual meaning to those skilled in the art (not limited to any special or customized meaning), and includes, but is not limited to, saturated and unsaturated oils and waxes, derivatives, amides, glycerides, fatty acids, fatty alcohols, sterols and sterol derivatives, phospholipids, ceramides, sphingolipids, tocopherols, and carotenoids.

[0077] As used herein, the term “pharmaceutically acceptable” is a broad term and should be given its usual customary meaning to those skilled in the art (but not limited to any special or customized meaning), referring to, but not limited to, compounds, materials, compositions, and / or dosage forms that are within the bounds of sound medical judgment suitable for contact with human and animal tissues and / or consumption by humans and animals without undue toxicity, irritation, allergic reactions, or complications of other problems commensurate with a reasonable risk-benefit ratio.

[0078] The terms “pharmaceutically acceptable salt” and “pharmaceutically acceptable salt thereof,” as used herein, are broad terms, and their ordinary and conventional meanings should be given to those skilled in the art (not limited to special or customized meanings), referring to, but not limited to, salts prepared from pharmaceutically acceptable non-toxic acids or bases. Suitable pharmaceutically acceptable salts include metal salts, e.g., salts of aluminum, salts of zinc; alkali metal salts, e.g., salts of lithium, sodium, and potassium; alkaline earth metal salts, e.g., salts of calcium and magnesium; organic salts, e.g., salts of lysine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), procaine, and Tris; salts of free acids and free bases; inorganic salts, e.g., sulfates, hydrochlorides, and hydrobroms; and other salts from sources currently widely used pharmaceutically and well known to those skilled in the art, e.g., listed in The Merck Index. Any suitable components can be selected to prepare salts of the therapeutic agents discussed herein, provided that they are nontoxic and do not substantially interfere with the desired activity. In addition to salts, pharmaceutically acceptable precursors and derivatives of the compounds can be used. Pharmaceutically acceptable amides, lower alkyl derivatives, and protecting derivatives may also be suitable for use in the compositions and methods of the preferred embodiments. While it may be possible to administer the compounds of the preferred embodiments in the form of pharmaceutically acceptable salts, it is generally preferred to administer the compounds in a neutral form.

[0079] The term “pharmaceutical composition,” as used herein, is a broad term and should be given its usual and customary meaning to those skilled in the art (not limited to any special or customized meaning), referring to, but not limited to, a mixture of one or more of the compounds disclosed herein with other chemical components such as diluents or carriers. Pharmaceutical compositions facilitate the administration of compounds to living organisms. Pharmaceutical compositions can also be obtained by reacting compounds with inorganic or organic acids or bases. Pharmaceutical compositions are generally formulated to suit a specific intended route of administration.

[0080] As used herein, “carrier” is a broad term and should be given its usual, conventional meaning to those skilled in the art (not limited to any special or customized meaning), referring to, but not limited to, compounds that facilitate the uptake of a compound into a cell or tissue. For example, but not limited to, dimethyl sulfoxide (DMSO) is a commonly used carrier that facilitates the uptake of many organic compounds into target cells or tissues. Water, saline solution, ethanol, and mineral oil are also carriers used in certain pharmaceutical compositions.

[0081] As used herein, “diluent” is a broad term and should be given its usual and customary meaning to those skilled in the art (not limited to any special or customized meaning), referring to, but not limited to, components in a pharmaceutical composition that lack pharmacological activity but may be pharmaceutically necessary or desirable. For example, a diluent may be used to increase the bulk of a potent drug whose mass is too small for manufacture and / or administration. It may also be a liquid for dissolving a drug administered by injection, ingestion, or inhalation. Common forms of diluents in the art are, but not limited to, buffered aqueous solutions such as phosphate-buffered saline that mimics the composition of human blood.

[0082] As used herein, “excipient” is a broad term and should be given its usual and customary meaning to those skilled in the art (not limited to any special or customized meaning), referring to a substance added to a pharmaceutical composition to provide the composition with bulk, consistency, stability, binding ability, lubrication, disintegration ability, etc. “Diluent” is a type of excipient.

[0083] As used herein, “subject” is a broad term and should be given its usual and customary meaning to those skilled in the art (not limited to any special or customized meaning), referring to, but not limited to, animals that are the subject of treatment, observation or experimentation. “Animal” includes cold-blooded and warm-blooded vertebrates, as well as invertebrates such as fish, mollusks, and reptiles, and mammals in particular. “Mammals” are not limited to, but include, dolphins, mice, rats, rabbits, guinea pigs, dogs, cats, sheep, goats, cattle, horses, primates such as monkeys, chimpanzees, and apes, and humans in particular. In some embodiments, the subject is human.

[0084] As used herein, the terms “to treat,” “treatment,” “therapeutic,” or “treatment” are broad terms and should be given their usual, customary meanings (not limited to any special or customized meanings), but not necessarily meaning the complete cure or elimination of a disease or condition. Any relief of any undesirable marker, sign, or symptom of a disease or condition may be considered treatment and / or therapy to any degree. Furthermore, treatment may include actions that may worsen the patient’s overall well-being or appearance.

[0085] The terms “therapeutic dose” and “effective dose,” as used herein, are broad terms and should be given their ordinary and customary meanings to those skilled in the art (not limited to special or customized meanings) and are used without limitation to indicate the amount of an active compound or pharmaceutically active substance that elicits an indicated biological or pharmaceutical response. For example, a therapeutic dose of a compound may be the amount necessary to prevent, alleviate or improve a marker or symptom of a condition, or the amount necessary to prolong the survival of the subject being treated. This response may occur in tissues, systems, animals, or humans and may include the alleviation of signs or symptoms of the disease being treated. Determining a therapeutic dose is well within the capabilities of those skilled in the art, given the disclosures provided herein. The therapeutic dose of a compound disclosed herein required as a dose depends on the route of administration, the type of animal being treated, including humans, and the physical characteristics of the particular animal being considered. Dosages can be adjusted to achieve the desired effect, but depend on factors such as body weight, diet, concomitant drug therapy, and other factors recognized by those skilled in the art in the medical field.

[0086] The term “solvent,” as used herein, is a broad term and should be given to those skilled in the art its usual and customary meaning (not limited to any special or customized meaning), and can be polar or nonpolar, linear or branched, cyclic or aliphatic, aromatic, or naphthenic, and refers to, but is not limited to, alcohols, derivatives, diesters, ketones, acetates, terpenes, sulfoxides, glycols, paraffins, hydrocarbons, anhydrides, and heterocyclic compounds, as well as compounds having certain characteristics of solubility in other compounds or means.

[0087] As used herein, the term “substantially not containing” means containing 15% by weight or less, 10% by weight or less, 9% by weight or less, 8% by weight or less, 7% by weight or less, 6% by weight or less, 5% by weight or less, 4% by weight or less, 3% by weight or less, 2% by weight or less, or 1% by weight or less of another fatty acid.

[0088] The term "about" as used herein means a reference quantity, level, value, number, frequency, percentage, dimension, size, volume, weight, or length that varies by approximately 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1%. Where the term "about" precedes a value, the components shall not be strictly limited to that value, but shall include quantities that vary from that value.

[0089] Any percentages, ratios, or other quantities mentioned herein are based on weight unless otherwise specified.

[0090] (odd chain fatty acids) Examples of fatty acids include saturated and unsaturated fatty acids, as provided herein, and fatty acids are referred to and described using conventional nomenclature as used by those skilled in the art. Saturated fatty acids do not contain carbon-carbon double bonds. Unsaturated fatty acids contain at least one carbon-carbon double bond. Monounsaturated fatty acids contain only one carbon-carbon double bond. Polyunsaturated fatty acids contain two or more carbon-carbon double bonds. Double bonds in fatty acids are generally cis, but trans double bonds are also possible. The position of a double bond can be indicated by Δn, where n is the lower-numbered carbon in each pair of double-bonded carbon atoms. Total # carbons: # double bonds, Δ 二重結合位置 A simplified notation in the form of 20:4Δ can be used. 5,8,11,14 C20:4 refers to a fatty acid having 20 carbon atoms and 4 double bonds, where the double bonds are located between 5-6 carbon atoms, 8-9 carbon atoms, 11-12 carbon atoms, and 14-15 carbon atoms, with carbon atom 1 being the carbon atom of the carboxylic acid group. Stearic acid (octadecanoate) is a saturated fatty acid. Oleate (cis-Δ9-octadecenoate) is a monounsaturated fatty acid, and linolenic acid (total cis-Δ9,12,15-octadecatrienoate) is a polyunsaturated fatty acid. The total number of carbon atoms can precede "C", and the position of the double bonds does not need to be specified; for example, C20:4 refers to a fatty acid having 20 carbon atoms and 4 double bonds.

[0091] Fatty acids can be referred to by various names; for example, heptadecanoic acid may be called heptadecylic acid, margaric acid, and n-heptadecylic acid, or C17:0. Fatty acids can also be referred to by their lipid number, as is known in the art.

[0092] In some embodiments, the fatty acids may be odd-chain saturated fatty acids. In further embodiments, one or more fatty acids may include at least one odd-chain saturated fatty acid.

[0093] Examples of odd-chain fatty acids include margaric acid (heptadecanoic acid, C17:0), pelargonate (nonanoic acid, C9:0), undecanoic acid (C11:0), nonadecanoic acid (C19:0), pentadecanoic acid (C15:0), arachidonate ((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid), adrenaline (all-cis-7,10,13,16-docosatetraenoic acid), and osbondic acid (all-cis-4,7,10,13,16-docosapentaenoic acid). Generally, one or more odd-chain fatty acids have 9 to 31 carbon atoms (9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, or 31 carbon atoms), for example, 15 to 21 carbon atoms, for example, 17 carbon atoms, but in certain embodiments, a higher or lower odd number of carbon atoms may be permitted. Generally, one or more odd-chain fatty acids are saturated, but in certain embodiments, monounsaturated or polyunsaturated odd-chain fatty acids may be permitted.

[0094] Odd-chain fatty acids may include saturated or unsaturated hydrocarbon chains. Odd-chain fatty acids may exist as carboxylic acid derivatives. Odd-chain fatty acids may exist as salts, for example, on a carboxyl group. In some embodiments, one odd-chain fatty acid may be present, two odd-chain fatty acids may be present, three odd-chain fatty acids may be present, or more. In some embodiments, odd-chain fatty acids in a mixture containing multiple odd-chain fatty acids may be distinguished by the amount of unsaturation, the length of the hydrocarbon chain, various states of derivatization, or other structural characteristics.

[0095] Odd-chain fatty acids are found in trace amounts in some dairy products, including butter (see, e.g., Mansson HL (2008), Fatty acids in bovine milk fat, Food Nutr. Res. 52:4). Multiple studies have demonstrated that increasing daily dietary intake of foods containing odd-chain fatty acids successfully increases serum or plasma levels (see, e.g., Benatar JR, Stewart RAH (2014), Effects of changes in dairy intake on trans and saturated fatty acid levels—Results from a randomized controlled study, Nutr. J. 13:32).

[0096] Generally, fatty acids such as odd-chain fatty acids can be provided as free fatty acids or derivatives thereof. Examples of such derivatives include, but are not limited to, acylglycerides. Acylglycerides may be substituted with up to three acyl fatty acid esters. Therefore, acylglycerides may be monoacylglycerides (MAG), diacylglycerides (DAG), or triacylglycerides (TAG). Glycerides may contain two or more fatty acid esters. For example, glycerides may contain heptadecanoates and docosanoates. Glycerides may also be structured triacylglycerides (STAG), plasmalogens, or phospholipids. Fatty acid esters may be located at the sn1 position, the sn2 position, or both. The sn1 and sn2 positions may be substituted with the same or different fatty acid esters. As a non-limiting example, structured triacylglycerides can be sn-1,3-C17-sn-2-oleoil.

[0097] In some embodiments, fatty acids may be provided as free fatty acids, cholesterol esters, glycerol esters (including, but not limited to, monoacylglycerides (MAG), diacylglycerides (DAG), or triacylglycerides (TAG)), phospholipids (including, but not limited to, phosphatidylcholine, lysophosphatidylcholine, phosphatidylethanolamine, lysophosphatidylethanolamine, or phosphatidylserine), ceramides (including, but not limited to, hexosylceramide), or sphingolipids. An unspecified example of phosphatidylcholine is 2,3-di-C17:0-phosphatidylcholine. An unspecified example of lysophosphatidylcholine is 2-lyso-3-C17:0-phosphatidylcholine. In some embodiments, the fatty acid derivatives may be β-sulfenyl derivatives. β-sulfenyl derivatives, such as acids or esters, are thought to be resistant to β-oxidation in the body. As a non-limiting example, a β-sulfenyl derivative of heptadecanoic acid is tetradecylthioacetic acid. The derivative can be synthesized by standard methods known to those skilled in the art.

[0098] In some embodiments, fatty acids may be provided as components of certain types of lipids, such as ceramides, phospholipids, sphingolipids, membrane lipids, glycolipids, or triglycerides.

[0099] In some embodiments, fatty acids, such as very long even-chain fatty acids, are provided in a bioavailable form. The term “bioavailability” is one of the key pharmacokinetic properties of a drug and refers to the percentage of an administered dose of the drug that reaches systemic circulation unchanged. By definition, when a drug is administered intravenously, its bioavailability is 100%. As used herein, the term “bioavailable” refers to a form of fatty acid that is well absorbed by the body when administered by a method other than intravenous administration, such as when using an oral therapeutic agent. In some embodiments, very long-chain fatty acid-based compositions may include adaptations to optimize absorption. In some embodiments, very long even-chain fatty acids can be provided as structured triacylglycerides. In further embodiments, the fatty acid is located at the sn-2 position of the structured triacylglyceride.

[0100] Pure or refined fatty acids can exist in a variety of physical states. For example, heptadecanoic acid exists as a stable off-white powder at room temperature, and this compound can be purchased in small quantities in a form suitable for research purposes from several commercial suppliers (e.g., Sigma-Aldrich, St. Louis, Missouri). Other fatty acids, or their salts or derivatives, can exist as oils, solids, crystalline solids, or gases.

[0101] Odd-chain fatty acids or their pharmaceutically acceptable salts or derivatives may be supplied in a purity of at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, at least about 99.9%, at least about 99.99%, or substantially pure (e.g., a percentage of bulk fatty acids or their pharmaceutically acceptable salts or derivatives thereof), where substantially pure may include, but is not limited to, products with impurities at levels such that the physiological effects from the presence of impurities are undetectable. Fatty acids, such as odd-chain fatty acids and / or very long-chain even-chain fatty acids, or mixtures of pharmaceutically acceptable salts thereof or derivatives thereof, may be present in amounts of at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, at least about 99.9%, at least about 99.99%, or substantially pure purity. Fatty acids, or mixtures thereof, or pharmaceutically acceptable salts thereof or derivatives thereof may not contain other fatty acids or fatty acid derivatives, may not contain triglycerides, or may not contain phospholipids. Odd-chain fatty acids provided herein may not substantially contain even-chain fatty acids, either alone or as a group; even-chain fatty acids include, for example, myristic acid (C14:0), palmitic acid (C16:0), or stearic acid (C18:0). In some embodiments, odd-chain fatty acids provided herein may not substantially contain short-chain fatty acids (SCFAs, e.g., fatty acids having 2 to 6 carbon atoms), medium-chain fatty acids (MCFAs, e.g., fatty acids having 7 to 12 carbon atoms), long-chain fatty acids (LCFAs, e.g., fatty acids having 13 to 22 carbon atoms), or very long-chain fatty acids (VLCFAs, e.g., fatty acids having 23 or more carbon atoms).

[0102] Fatty acids, such as odd-chain fatty acids or their pharmaceutically acceptable salts or derivatives thereof, may originate from any source. In some embodiments, fatty acids, or their pharmaceutically acceptable salts or derivatives thereof, may be present in natural sources, isolated from natural sources, semi-synthesized, synthetic, or a mixture of one or more thereof. Fatty acids, or their pharmaceutically acceptable salts or derivatives thereof, may be produced in the laboratory, produced naturally, produced by enzymatic processes, produced by wild microorganisms, produced by genetically modified microorganisms, isolated from animal tissues, produced by chemosynthesis, or produced by a combination of these processes.

[0103] Fatty acids may be derived from natural sources, such as fish oil, or they may be synthesized by methods known in the art. In some embodiments, fatty acids may be contaminated with undesirable components present in unrefined or unrefined natural products. In such situations, it may be desirable to remove the undesirable components or to increase the concentration of the desired components using known separation or purification techniques.

[0104] For any compound described, all tautomers are intended to be included. However, all tautomers of the carboxyl group are intended to be included, though not limited to them.

[0105] In any compound described herein having one or more double bonds that produce geometric isomers that can be defined as E or Z, each double bond may independently be E or Z, or a mixture thereof.

[0106] If the compounds disclosed herein have an unfilled valence, the valence should be filled with hydrogen or its isotopes, such as hydrogen-1 (protium) and hydrogen-2 (deuterium).

[0107] As described herein, fatty acids, such as odd-chain fatty acids, include crystalline forms (also known as polymorphs, which include different crystalline packing arrangements of the same elemental composition of the compound), amorphous phases, salts, solvates, and hydrates. In some embodiments, the compounds described herein exist in solvated forms with pharmaceutically acceptable solvents such as water and ethanol. In other embodiments, the compounds described herein exist in non-solvated forms. Solvates contain either stoichiometric or non-stoichiometric amounts of solvent and can be formed during a crystallization process using pharmaceutically acceptable solvents such as water and ethanol. Hydrates are formed when the solvent is water, or alkoxides are formed when the solvent is alcohol. Furthermore, the compounds provided herein can exist in both non-solvated and solvated forms. Generally, the solvated forms are considered equivalent to the non-solvated forms for the purposes of the compounds and methods provided herein.

[0108] The compounds described herein can be isotoped. In some circumstances, substitution with isotopes, such as deuterium, may provide certain therapeutic benefits resulting from greater metabolic stability, such as an increased in vivo half-life or reduced dose requirements. Isotope substitution may be beneficial in monitoring a subject's response to the administration of a compound, for example, by providing an opportunity to monitor the fate of atoms in the compound. Each chemical element as represented in the compound structure may contain any isotope of that element. For example, in the compound structure, a hydrogen atom may be explicitly disclosed or understood to be present in the compound. At any position in the compound where a hydrogen atom may be present, the hydrogen atom may be any isotope of hydrogen, including but not limited to hydrogen-1 (protium) and hydrogen-2 (deuterium). Thus, references to compounds herein encompass all potential isotopic forms unless the context clearly indicates otherwise.

[0109] The prevalence of various dietary fatty acids is correlated with the development of metabolic syndrome in the subjects (e.g., Forouhi N, Koulman A, Sharp S, Imamura F, Kroger J, Schulze M et al. (2014), Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study. Lancet Diabetes Endocrinol. 2:810-8). In fact, whole-fat dairy intake is associated with a reduced risk of metabolic syndrome markers (see, for example, Kratz M, Marcovina S, Nelson JE, Yeh MM, Kowdley KV, Callahan HS et al. (2014), Dairy fat intake is associated with glucose tolerance, hepatic and systemic insulin sensitivity, and liver fat but not beta-cell function in humans, Am.J.Clin.Nutr., 99:1385-96).

[0110] The mechanisms by which odd-chain saturated fatty acids have beneficial effects are not fully understood. While we do not wish to be limited by theory, it is thought that fatty acids or their derivatives may be elongated (increased chain length) or shortened by metabolic processes in the body to form different fatty acids or their derivatives. Peroxidation of certain fatty acids may produce products with signaling properties in the body. Fatty acids of certain chain lengths are thought to produce signaling products that substantially contribute to one or more of the conditions provided herein. In some embodiments, odd-chain fatty acids are elongated to form very long-chain fatty acids, such as very long-chain even-chain fatty acids. In further embodiments, very long-chain even-chain fatty acids may be shortened to odd-chain fatty acids. Levels of very long-chain even-chain fatty acids in the body may increase after administration of one or more odd-chain fatty acids. Levels of odd-chain fatty acids in the body may increase after administration of one or more very long-chain even-chain fatty acids.

[0111] (A pharmaceutical composition containing one or more fatty acids) A formulation is provided comprising a fatty acid such as an odd-chain fatty acid or an extra-long-chain even-chain fatty acid, or a salt thereof or a derivative thereof, and at least one excipient. In oral formulations, administration of the compounds of the embodiments is generally preferred, but other routes of administration are also intended.

[0112] The pharmaceutical compositions described herein may be administered to a subject on their own, or they may be administered in combination with other activators as part of a combination therapy, or in a composition mixed with carriers, diluents, excipients, or combinations thereof. The formulation depends on the chosen route of administration. The techniques for formulation and administration of the compounds described herein are known to those skilled in the art (e.g., "Remington: The Science and Practice of Pharmacy," Lippincott Williams & Wilkins; 20th edition (June 1, 2003) and "Remington's Pharmaceut," Ltd., 18th and 19th editions (December 1985 and June 1990)).

[0113] The pharmaceutical compositions disclosed herein can be prepared by methods known in themselves, for example, by conventional mixing, dissolution, granulation, sugar-coated tablet production, levigation, emulsification, encapsulation, encapsulation, tableting, or extraction methods. Many of the compounds used in the pharmaceutical combinations disclosed herein may be provided as salts with pharmaceutically acceptable counterions.

[0114] Multiple techniques for administering compounds exist in the art, including, but are not limited to, oral, rectal, topical, aerosol, injection, and parenteral delivery, including intramuscular, subcutaneous, intravenous, intrathecal, intrathecal, direct intraventricular, intraperitoneal, intranasal, and intraocular injections. This specification considers any of the aforementioned methods, or any combination thereof, known to those skilled in the art (e.g., "Remington: The Science and Practice of Pharmacy," Lippincott Williams & Wilkins; 20th edition (June 1, 2003) and "Remington's Pharmaceutical Sciences," Mack Pub. Ltd., 18th and 19th editions (December 1985 and June 1990)).

[0115] In practice, fatty acids, such as odd-chain saturated fatty acids or their salts or derivatives, can be combined as active ingredients in a tight mixture with a pharmaceutical carrier according to conventional pharmaceutical formulation techniques. The carrier can take a wide variety of forms depending on the desired form of the preparation for administration. Thus, the pharmaceutical compositions provided herein can be provided as individual units suitable for oral administration, such as capsules, cachets, or tablets, each containing a predetermined amount of the active ingredient. Furthermore, the compositions can be provided as oils, powders, granules, solutions, suspensions in aqueous liquids, non-aqueous liquids, oil-in-water emulsions, or water-in-oil liquid emulsions. In addition to the general dosage forms described above, the compounds provided herein, or their pharmaceutically acceptable salts or derivatives, can also be administered by controlled release means and / or delivery devices. The compositions can be prepared by any of the pharmaceutical methods. Generally, such methods include the step of associating the active ingredient with a carrier constituting one or more required components. Generally, the compositions are prepared by uniformly and closely mixing the active ingredient with a liquid carrier or a micronized solid carrier or both. The product can then be conveniently molded into the desired presentation.

[0116] The formulations may also be administered topically rather than systemically, for example, by direct injection of the compound into the infected area, often in depot or sustained-release formulations. Furthermore, targeted drug delivery systems may be used, for example, in liposomes coated with tissue-specific antibodies.

[0117] The pharmaceutical composition may contain fatty acids, such as odd-chain fatty acids, or their salts or derivatives, in amounts effective for the desired therapeutic effect. In some embodiments, the pharmaceutical composition is a unit dosage form, containing about 1 mg or less to about 5000 mg or more per unit dosage form. In further embodiments, the pharmaceutical composition contains about 1 to about 500 mg or about 500 to 5000 mg per unit dosage form. Such dosage forms may be solid, semi-solid, liquid, emulsion, or adapted for delivery via aerosols or the like for inhalation administration.

[0118] The pharmaceutical carriers used may be solids, liquids, or gases. Examples of solid carriers include lactose, clay, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Examples of liquid carriers include sugar syrup, peanut oil, olive oil, lower alcohols, and water. Examples of gaseous carriers include carbon dioxide and nitrogen.

[0119] The pharmaceutical compositions provided herein can be prepared as solutions or suspensions of active compounds in water. Suitable surfactants, such as hydroxypropyl cellulose, may be included. Dispersions can also be prepared in glycerol, liquid polyethylene glycol, and mixtures thereof in oil. Furthermore, preservatives may be included, for example, to prevent the harmful growth of microorganisms.

[0120] The pharmaceutical compositions provided herein for use in injection include sterile aqueous solutions or dispersions. Furthermore, the compositions may be in the form of sterile powders for the immediate preparation of such sterile injection solutions or dispersions. The pharmaceutical compositions must be stable under manufacturing and storage conditions; therefore, they should preferably be protected from contamination by microorganisms such as bacteria and fungi. The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.

[0121] In addition to the carrier components described above, the pharmaceutical formulations described above may optionally include one or more additional carrier components such as diluents, buffers, flavoring agents, binders, surfactants, thickeners, lubricants, and preservatives (including antioxidants). Furthermore, other adjuvants may be included to make the formulation isotonic with the blood of the intended recipient. Compositions containing the compounds provided herein, or pharmaceutically acceptable salts or derivatives thereof, may also be prepared in the form of powders or liquid concentrates for dilution.

[0122] Fatty acids, such as odd-chain saturated fatty acids, or their salts or derivatives, can be formulated as liposomes. The fatty acids may be components of the lipid portion of the liposome or encapsulated in the aqueous portion. Fatty acids, such as odd-chain fatty acids, or their salts or derivatives, can also be co-formulated with cyclodextrins. The cyclodextrins may be, for example, hydroxypropyl-β-cyclodextrin or sulfobutyl ether cyclodextrin.

[0123] This specification envisions compositions comprising fatty acids, such as odd-chain saturated fatty acids, or salts thereof or derivatives thereof, in combination with at least one additional activator. The fatty acids, e.g., odd-chain saturated fatty acids, or salts thereof or derivatives thereof, and at least one additional activator may be present in a single formulation or in multiple formulations provided together, or may not be formulated (e.g., without excipients and carriers). In some embodiments, fatty acids, such as odd-chain saturated fatty acids, or salts thereof or derivatives thereof, may be administered together with one or more additional agents in a single composition. For example, a compound of a fatty acid, such as an odd-chain saturated fatty acid, or a salt thereof or derivative thereof, may be administered in one composition, and at least one of the additional agents may be administered in a second composition. In further embodiments, fatty acids, such as odd-chain saturated fatty acids, or salts thereof or derivatives thereof, and at least one additional activator may be co-packaged in a kit. For example, a drug manufacturer, drug reseller, physician, compound store, or pharmacist may provide a kit comprising the disclosed compound or product and other components for delivery to a patient.

[0124] Some embodiments described herein relate to pharmaceutical compositions that may comprise a therapeutically effective amount of one or more of the compounds described herein (e.g., fatty acids such as odd-chain saturated fatty acids or pharmaceutically acceptable salts thereof or derivatives thereof) and a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof. The pharmaceutical composition may contain, for example, >1%, ≥2%, ≥3%, ≥4%, ≥5%, ≥6%, ≥7%, ≥8%, ≥9%, ≥10%, ≥20%, ≥30%, ≥40%, ≥50%, ≥60%, ≥70%, ≥80%, ≥90%, ≥95%, or ≥98% of the composition of fatty acids such as odd-chain saturated fatty acids, or salts thereof or derivatives thereof. In some embodiments, the pharmaceutical composition may contain a plurality of fatty acids, for example, one or more odd-chain saturated fatty acids and / or very long-chain even-chain fatty acids of the composition, or salts thereof or derivatives thereof, in amounts such as >1%, ≥2%, ≥3%, ≥4%, ≥5%, ≥6%, ≥7%, ≥8%, ≥9%, ≥10%, ≥20%, ≥30%, ≥40%, ≥50%, ≥60%, ≥70%, ≥80%, ≥90%, ≥95%, or ≥98%.

[0125] (food) Foods, dietary supplements, and other food products containing fatty acids, such as odd-chain saturated fatty acids, or salts thereof or derivatives thereof, are provided, in which the amount of fatty acids in the food is fortified (e.g., concentrated or concentrated). The fatty acids provided herein, such as odd-chain saturated fatty acids, may be added to food for consumption by the target. Fatty acids, such as odd-chain saturated fatty acids, may be incorporated into one or more components of food. Fatty acids, such as odd-chain saturated fatty acids, may or may not be prepared as components. Compounds or preparations containing compounds may be added before, during, or after preparation. Preparations may include, but are not limited to, cooking, mixing, flavoring, seasoning, blending, boiling, frying, baking, or other processes known in the art. Fortification is preferably at a level that provides a therapeutic daily dose of the fatty acid as described elsewhere herein; however, beneficial effects may also be obtained at amounts less than such doses.

[0126] Fatty acids, such as odd-chain saturated fatty acids, or their salts or derivatives, provided herein may be present as components in food by manipulating naturally known processes, for example, by altering the metabolic processes of plants, animals, bacteria, or fungi. Genetic modification of plants, animals, bacteria, or fungi is attempted to increase the concentration of fatty acids, such as odd-chain saturated fatty acids, or their salts or derivatives. For example, fatty acids may be present in food at concentrations of at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least 20%, at least 30%, at least about 40%, at least about 50%, or more, for example, 1%-2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, or 50%.

[0127] (Indications) Compositions and methods are provided for supporting a healthy weight, assisting in the maintenance of the body mass index, promoting a reduction in the body mass index, promoting satiety, promoting a reduction in calorie expenditure, and / or promoting efficient fat metabolism. These compositions comprise one or more odd-chain saturated fatty acids, derivatives of odd-chain saturated fatty acids, or salts thereof, which may be administered in combination with other drugs or supplements, or as part of various therapeutic regimens as described herein. Pentadecanoic acid has these activities in humans at daily oral intakes ranging from less than 1 mg / day to more than 500 mg / day, for example, 0.2 mg / day to 20 mg / day, 1.0 mg / day to 5.0 mg / day, 5 mg / day to 50 mg / day, 20 mg / day to 200 mg / day, for example, 100 mg / day.

[0128] While we do not wish to be limited by theory, it is thought that increasing odd-chain saturated free fatty acids or phospholipid levels in serum, plasma, and cells to target concentrations may elevate and / or enhance mood, reduce anxiety and / or pain, treat depression, treat major depressive disorder, or treat seasonal affective disorder.

[0129] In some embodiments, the methods provided herein increase the levels of odd-chain fatty acids in serum, plasma, or red blood cell membranes.

[0130] In some embodiments, levels of very long-chain even-chain fatty acids in serum, plasma, or red blood cell membranes may increase after administration of one or more odd-chain fatty acids, their salts, or derivatives thereof.

[0131] Provided herein is a therapeutic method comprising the step of administering a certain dose of a fatty acid, for example, an odd-chain fatty acid or an extra-long-chain even-chain fatty acid, at predetermined intervals or at intervals left to the discretion of the subject.

[0132] In some embodiments, the compounds and methods provided herein may provide a threshold serum, plasma, or erythrocyte membrane percentage of odd-chain fatty acids relative to all serum, plasma, or erythrocyte membrane fatty acids. For example, the threshold may be a value between approximately 0.05% and 90% or more, e.g., at least approximately 0.05%, at least approximately 0.1%, at least approximately 0.2%, at least approximately 0.3%, at least approximately 0.4%, at least approximately 0.5%, at least approximately 0.6%, at least approximately 0.7%, at least approximately 0.8%, at least approximately 0.9%, at least approximately 1.0%, at least approximately 1.1%, at least approximately 1.2%, at least approximately 1.3%, at least approximately 1.4%, at least approximately 1.5%, at least approximately 1.6%, at least approximately 1.7%, at least approximately 1.8%, at least approximately 1.9%, at least approximately 2.0%, at least approximately 2.1%, at least approximately 2.2%, and less It could be at least 2.3%, at least 2.4%, at least 2.5%, at least 2.6%, at least 2.7%, at least 2.8%, at least 2.9%, at least 3.0%, at least 3.5%, at least 4.0%, at least 4.5%, at least 5%, at least 6%, at least 7%, at least 8%, at least 9%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more than 90%.

[0133] In some embodiments, the compounds and methods provided herein can provide an increase in the serum or plasma concentration of odd-chain fatty acids, or the erythrocyte membrane concentration of odd-chain fatty acids, above a baseline value (e.g., a pretreatment value in a patient being treated, or a general value observed in a particular patient population). For example, the serum or plasma odd-chain fatty acid or erythrocyte membrane concentration of odd-chain fatty acids can increase by at least about 1 μg / ml, at least about 2 μg / ml, at least about 3 μg / ml, at least about 4 μg / ml, at least about 5 μg / ml, at least about 6 μg / ml, at least about 7 μg / ml, at least about 8 μg / ml, at least about 9 μg / ml, at least about 10 μg / ml, at least about 15 μg / ml, at least about 20 μg / ml, at least about 25 μg / ml, at least about 30 μg / ml, at least about 35 μg / ml, at least about 40 μg / ml, at least about 45 μg / ml, at least about 50 μg / ml, or more than 50 μg / ml. In some embodiments, the concentration of odd-chain fatty acids in serum, or the concentration of odd-chain fatty acids in erythrocyte membranes, is at least about 0.01x10 -4 M, at least about 0.05x10 -4 M, at least about 0.1x10 -4 M, at least about 0.2x10 -4 M, at least about 0.3x10 -4 M, at least about 0.4x10 -4 M, at least about 0.5x10 -4 M, at least about 0.6x10 -4 M, at least about 0.7x10 -4 M, at least about 0.8x10 -4 M, at least about 0.9x10 -4 M, at least about 1x10 -4 M, at least about 2x10 -4 M, or at least about 3x10 -4 M, and can increase.

[0134] In some embodiments, the compounds and methods provided herein may provide an increase in serum or plasma total odd-chain fatty acids, or erythrocyte membrane total odd-chain fatty acids. For example, serum total odd-chain fatty acids, or erythrocyte membrane total odd-chain fatty acids, may be increased by at least about 5 μg / ml, at least about 6 μg / ml, at least about 7 μg / ml, at least about 8 μg / ml, at least about 9 μg / ml, at least about 10 μg / ml, at least about 15 μg / ml, at least about 20 μg / ml, at least about 25 μg / ml, at least about 30 μg / ml, at least about 35 μg / ml, or at least about 40 μg / ml compared to baseline values ​​(e.g., pre-treatment values ​​in patients undergoing treatment, or typical values ​​observed in a particular patient population). The levels may increase to μg / ml, at least about 45 μg / ml, at least about 50 μg / ml, at least about 60 μg / ml, at least about 70 μg / ml, at least about 80 μg / ml, at least about 90 μg / ml, at least 100 μg / ml, at least about 150 μg / ml, at least about 200 μg / ml, at least about 250 μg / ml, at least about 300 μg / ml, at least about 350 μg / ml, at least about 400 μg / ml, at least about 450 μg / ml, at least about 500 μg / ml, or more than 500 μg / ml.

[0135] In some embodiments, the compounds and methods provided herein may provide increases in serum, plasma, or erythrocyte membrane odd-chain fatty acids that exceed baseline values ​​(e.g., pretreatment values ​​in a treated patient, or general values ​​observed in a particular patient population), compared to all serum or erythrocyte membrane fatty acids, respectively. For example, serum, phenotype, or erythrocyte membrane odd-chain fatty acids may increase by at least about 0.01%, at least about 0.05%, at least about 0.1%, at least about 0.2%, at least about 0.3%, at least about 0.4%, at least about 0.5%, at least about 0.6%, at least about 0.7%, at least about 0.8%, at least about 0.9%, at least about 1%, at least about 1.1%, at least about 1.2%, at least about It may increase by 1.3%, at least about 1.4%, at least about 1.5%, at least about 1.6%, at least about 1.7%, at least about 1.8%, at least about 1.9%, at least about 2%, at least about 2.1%, at least about 2.2%, at least about 2.3%, at least about 2.4%, at least about 2.5%, at least about 2.6%, at least about 2.7%, at least about 2.8%, at least about 2.9%, at least about 3%, at least about 3.5%, at least about 4%, at least about 4.5%, or at least about 5% or more than 5%.

[0136] In some embodiments, the compounds and methods provided herein may provide a reduction in elevated erythrocyte sedimentation rate.

[0137] In some embodiments, the compounds and methods provided herein may provide a reduction in elevated alkaline phosphatase.

[0138] In some embodiments, the compounds and methods provided herein may provide a reduction in serum ferritin. For example, serum ferritin may be reduced by at least about 10 ng / ml, at least about 100 ng / ml, at least about 200 ng / ml, at least about 300 ng / ml, at least about 400 ng / ml, at least about 500 ng / ml, at least about 600 ng / ml, at least about 700 ng / ml, at least about 800 ng / ml, at least about 900 ng / ml, at least about 1000 ng / ml, at least about 1100 ng / ml, and at least about 1 It may decrease to 200 ng / ml, at least about 1300 ng / ml, at least about 1400 g / ml, at least about 1500 g / ml, at least about 2000 g / ml, at least about 2500 g / ml, at least about 3000 g / ml, at least about 3500 g / ml, 4000 ng / ml, at least about 4500 ng / ml, at least about 5000 ng / ml, at least about 6000 ng / ml, at least about 7000 ng / ml, at least about 8000 ng / ml, at least about 9000 ng / ml, at least about 10000 ng / ml, or more than 10000 ng / ml.

[0139] In some embodiments, the compounds and methods provided herein may provide a reduction in serum ferritin to below a certain level. For example, serum ferritin may be reduced to about 20,000 ng / ml, about 15,000 ng / ml, about 12,000 ng / ml, about 10,000 ng / ml, about 8,000 ng / ml, about 5,000 ng / ml, about 2,000 ng / ml, about 1,000 ng / ml, or less than about 500 ng.

[0140] In some embodiments, odd-chain fatty acids (e.g., saturated odd-chain fatty acids) are administered to maintain the serum or plasma total percentage of odd-chain fatty acids or all odd-chain fatty acids above a predetermined threshold. In variations of these embodiments, the odd-chain fatty acid is heptadecanoic acid. In further variations, odd-chain fatty acids, or all odd-chain fatty acids, are administered to maintain serum phospholipid percentages of approximately 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.2%, 1.4%, 1.6%, 1.8%, 2%, 2.2%, 2.4%, or 2.6%.

[0141] In some embodiments, the compounds and methods provided herein may provide a threshold serum, plasma, or erythrocyte membrane percentage of very long-chain even-chain fatty acids compared to all serum or erythrocyte membrane fatty acids. For example, the threshold values ​​range from approximately 0.05% to 90% or greater, e.g., at least approximately 0.05%, at least approximately 0.1%, at least approximately 0.2%, at least approximately 0.3%, at least approximately 0.4%, at least approximately 0.5%, at least approximately 0.6%, at least approximately 0.7%, at least approximately 0.8%, at least approximately 0.9%, at least approximately 1.0%, at least approximately 1.1%, at least approximately 1.2%, at least approximately 1.3%, at least approximately 1.4%, at least approximately 1.5%, at least approximately 1.6%, at least approximately 1.7%, at least approximately 1.8%, at least approximately 1.9%, at least approximately 2.1%, at least approximately 2.2%, at least approximately 2.3%, and at least approximately 2. It could be 4%, at least about 2.5%, at least about 2.6%, at least about 2.7%, at least about 2.8%, at least about 2.9%, at least about 3.0%, at least about 3.5%, at least about 4.0%, at least about 4.5%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more than 90%.

[0142] In some embodiments, the compounds and methods provided herein may provide an increase in serum or plasma concentration of very long-chain even-chain fatty acids, or in erythrocyte membrane concentration of very long-chain even-chain fatty acids, above baseline values ​​(e.g., pretreatment values ​​in the treated patient, or typical values ​​observed in a particular patient population). For example, the concentration of very long-chain fatty acids or red blood cell membranes can increase by at least about 0.01 μg / ml, at least about 0.05 μg / ml, at least about 0.1 μg / ml, at least about 0.4 μg / ml, 1 μg / ml, at least about 2 μg / ml, at least about 3 μg / ml, at least about 4 μg / ml, at least about 5 μg / ml, at least about 6 μg / ml, at least about 7 μg / ml, at least about 8 μg / ml, at least about 9 μg / ml, at least about 10 μg / ml, at least about 15 μg / ml, at least about 20 μg / ml, at least about 25 μg / ml, at least about 30 μg / ml, at least about 35 μg / ml, at least about 40 μg / ml, at least about 45 μg / ml, at least about 50 μg / ml, or more than 50 μg / ml. In some embodiments, serum concentrations of very long-chain even-chain fatty acids, or red blood cell membrane concentrations of very long-chain even-chain fatty acids, are at least about 0.001 × 10⁻¹⁴ higher than baseline values ​​(e.g., pre-treatment values ​​in patients undergoing treatment, or typical values ​​observed in a particular patient population). -4 M, at least about 0.005 × 10 -4 M, at least about 0.01 × 10 -4 M, at least about 0.05 × 10 -4 M, at least about 0.1 × 10 -4 M, at least about 0.2 × 10 -4 M, at least about 0.3 × 10 -4 M, at least about 0.4 × 10 -4 M, at least about 0.5 × 10 -4 M, at least about 0.6 × 10 -4 M, at least about 0.7 × 10 -4 M, at least about 0.8 × 10 -4 M, at least about 0.9 × 10 -4 M, at least about 1 × 10 -4M, at least about 2 × 10 -4 M, or at least about 3 × 10 -4 M can increase.

[0143] In some embodiments, the compounds and methods provided herein may provide an increase in total very long chain even fatty acids in serum or plasma, or in the total very long chain even fatty acids in the erythrocyte membrane. For example, serum total very long chain even fatty acids, or erythrocyte full-length membrane very long chain even fatty acids may be increased by at least about 0.05 μg / ml, at least about 0.1 μg / ml, at least about 0.5 μg / ml, at least about 1 μg / ml, at least about 5 μg / ml, at least about 6 μg / ml, at least about 7 μg / ml, at least about 8 μg / ml, at least about 9 μg / ml, at least about 10 μg / ml, at least about 15 μg / ml, at least about 20 μg / ml, at least about 25 μg / ml, and at least It can increase to approximately 30 μg / ml, at least approximately 35 μg / ml, at least approximately 40 μg / ml, at least approximately 45 μg / ml, at least approximately 50 μg / ml, at least approximately 60 μg / ml, at least approximately 70 μg / ml, at least approximately 80 μg / ml, at least approximately 90 μg / ml, at least approximately 100 μg / ml, at least approximately 150 μg / ml, at least approximately 200 μg / ml, at least approximately 250 μg / ml, at least approximately 300 μg / ml, at least approximately 350 μg / ml, at least approximately 400 μg / ml, at least approximately 450 μg / ml, at least approximately 500 μg / ml, or more than 500 μg / ml.

[0144] In some embodiments, compositions or methods provided herein may provide an increase in red blood cell count. For example, red blood cell count levels may increase by at least about 0.1 cells / μL, at least about 0.2 cells / μL, at least about 0.3 cells / μL, at least about 0.4 cells / μL, at least about 0.5 cells / μL, at least about 0.6 cells / μL, at least about 0.7 cells / μL, at least about 0.8 cells / μL, at least about 0.9 cells / μL, at least about 1 cell / μL, at least about 1.2 cells / μL, at least about 1.4 cells / μL, at least about 1.6 cells / μL, or at least about 2 cells / μL compared to a baseline value (e.g., a pre-treatment value in a patient undergoing treatment, or a typical value observed in a particular patient population).

[0145] (Combination therapy) In some embodiments, pharmaceutical compositions comprising compounds disclosed herein, for example, odd-chain fatty acids, or salts thereof or derivatives thereof, or very long-chain even-chain fatty acids, or salts thereof or derivatives thereof, or compounds described herein, or salts thereof or derivatives thereof, may be used in combination with one or more further activators. Examples of additional activators that can be used in combination with compositions comprising odd-chain fatty acid compounds, or salts thereof or derivatives thereof, or odd-chain fatty acid compounds, or salts thereof or derivatives thereof include, but are not limited to, drugs currently used to treat the conditions provided herein, and other drugs known in medicine.

[0146] In some embodiments, a compound of an odd-chain fatty acid, or a salt thereof or derivative thereof, or a composition comprising a compound of an odd-chain fatty acid, or a salt thereof or derivative thereof, may be used in conjunction with one, two, three, or more additional activators described herein. Such agents may include, but are not limited to, a second fatty acid such as an odd-chain fatty acid or a very long-chain even-chain fatty acid, or a salt thereof or derivative thereof. In some embodiments, the composition may contain at least one odd-chain fatty acid, or a salt thereof or derivative thereof, and at least one very long-chain even-chain fatty acid, or a salt thereof or derivative thereof.

[0147] In some embodiments, compounds of odd-chain fatty acids, or salts thereof or derivatives thereof, or compositions comprising compounds of odd-chain fatty acids, or salts thereof or derivatives thereof, may be used (e.g., administered or ingested) in combination with other agents for the purpose of raising and / or enhancing mood, reducing anxiety and / or pain, treating depression, treating major depressive disorder, or treating seasonal affective disorder.

[0148] For example, fatty acid compounds such as odd-chain fatty acids disclosed herein are used as stimulants (e.g., caffeine), statins (e.g., atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Altoprev), pitavastatin (Livalo), pravastatin (Pravachol), rosuvastatin (Crestor), simvastatin (Zocor)), cholesterol absorbers (e.g., ezetimibe (Zetia)), bile acid secretion inhibitors (e.g., cholestyramine (Prevalite), choleceveram (Welchol), colestipol (Colestid)), ezetimibe-simvastatin (Vytorin), alirocumab (Pralu ent), evolocumab (Repatha), PKSK9 inhibitors, fibrates (e.g., fenofibrate (Tricor), gemfibrozil), niacin, phytosterols, fish oil / omega-3 fatty acids, weight-loss agents (orlistat (Xenical), lorcaserin (Belviq), phentermine and topiramate (Qsymia), bupropion and naltrexone (Contrave), liraglutide (Saxenda), phentermine, adipex-P, topamax, desoxin, Ally, Xenical, fendimethrazine, Tenuate, Fastin, Qsymia, bupropion, diethylpropion, hCG, methamphetamine, Bontril Slow Release, Didrex, lorcaserin, Saxenda, lonamin, Pregnyl, BontrilPDM, chorionic gonadotropin, phentermine / topiramate, Tagamet, Topiragen, Xanthril, liraglutide, T-diet, Topamax sprinkle, amphetamine, benzphetamine, bupropion / naltrexone, cimetidine, Ibukio, methylphenidate, Splenza, Tenuto dospan, Adipost, Attiplex P, Belvic XR, desvenlafaxine, Romeira, Obicap, Fendito, Fentercot, Fentora Ido, Prelu-2, Tagamet HB, Equalin reducing agent, Melfia, Ovegene, Phendiet-105, Recede, Regimex, Tepanil, Garcinia, Guarana, Hoodia, Ephedra, Anticoagulants (Heparin, Warfarin, Apixaban, Dabigatran, Dalteparin, Edoxaban, Enoxaparin, Fondaparinux, Rivaroxaban, Betrixaban), Xa inhibitors, Antifibrotic drugs (Nintedanib, Pirfenidone, Epinephrine, NSAIDs, antihistamines, corticosteroids (cortisone, prednisolone), cyclophosphamide, azathioprine, mycophenolate mofetil, N-acetylcysteine, proton pump inhibitors (prilocein, nexium), bronchodilators (albuterol, theophylline, ipratropium), mucolytics (guaifenesin, DNase, N-acetylcysteine, hypertonic saline), anti-inflammatory drugs (triamcinolone, flunisolide, fluticasone, beclomethasone, plutonium) Rednisone, methylprednisone, ibuprofen, montelukast, cromolyn, N-acetylcysteine), antibiotics (ciprofloxacin, cotrimoxazole, tobramycin, cephalexin, colistin, dicloxaxillin, azithromycin, amoxicillin, cipro, levofloxacin, piperacillin, ceftozidime, meropenem, amoxicillin / clav, piperacillin, meropenem), vitamins (ADEK, Fer-in-Sol, Polyviflordrops, Aquasol-A, Aquasol-E, pancreatic enzymes (pancrelipase, pancreatin), stool softeners (doxate, casanthranol, polyethylene glycol), digestive system drugs (omeprazole, ranitidine, metoclopramide), antihistamines (loratadine, cetirizine, fexofenadine), nasal sprays (bansenase / ban AQ, beconase / beck AQ, sinus rinse), silver sulfadiazine, Santil, urea, Hibikuren, Silvaden, Viafine, Saruna, Benerex, Resed, RiaLO, Luxamend, Bionect, Nuvel, Revicin, Umeta, Dermasolve XM, Acticort, It can be used in combination with one or more drugs selected from Keragelt, silver nitrate, mafenide, sulfamilon, polysporine, X-Viate, Umecta PD, Uramaxin, Remeven, Keratritics, Neosporine, bacitracin, neomycin, polymyxin, bensal HP, atrapro, granurex, vasorex, zinc paste, calamine, coal tar, ichthammol, pentoxifylline, iloprost, glyceryl trinitrate, calcium channel blockers, corticosteroids, psoralen, phenytoin, retinoids, analgesics, colchicine, antiplatelet agents (aspirin), and vasoconstrictors (nicotine, cocaine, adrenaline).

[0149] The fatty acid compounds disclosed herein can be used in combination with one or more medical devices, medical procedures, or surgical procedures, such as surgical procedures for obesity (e.g., gastric bypass surgery, laparoscopic adjustable gastric band, biliary and pancreatic bypass with duodenal switch, gastric sleeve, vagus nerve block), catheter-directed thrombolysis, vena cava filters, venous thrombectomy, compression bandages, vacuum-assisted closure, intermittent pneumatic compression devices, debridement (such as sharp, mechanical, autolytic (honey), enzymatic, or biological surgery (maggot)), ultraviolet therapy, hyperbaric oxygen, radiant heat dressings, ultrasound therapy, lasers, hydrotherapy, electrotherapy, electromagnetic therapy, and immunoglobulin replacement therapy.

[0150] (Dosage) As will be readily apparent to those skilled in the art, the effective in vivo dose and specific mode of administration vary depending on age, weight, severity of condition, and mammalian species being treated, the specific form of the compound used, and the specific use in which these compounds are used. Determining the effective dose level, i.e., the dose level required to achieve the desired result, can be achieved by those skilled in the art using routine methods, such as in vivo studies. See, for example, “Estimating Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers,” U.S. Food and Drug Administration, July 2005.

[0151] In some embodiments, the methods provided herein may involve administering a therapeutically effective dose of the composition provided herein. In some embodiments, the therapeutically effective dose may be determined by reference to the modulation of markers of a condition associated with mood disorders or pain. In some embodiments, the therapeutically effective dose may be determined by reference to the modulation of symptoms of a condition provided herein. Further embodiments may include, but are not limited to, established guidelines for the treatment of conditions provided herein, including mood disorders or pain.

[0152] Dosages can vary widely depending on the desired effect and therapeutic indications, such as marker values. Alternatively, doses may be calculated based on the patient's surface area or weight, as understood by those skilled in the art. The exact dosage is determined on a case-by-case basis or, in some cases, left to the discretion of those with relevant information. Daily dosing regimens for adult human patients may include oral doses of, for example, fatty acids, such as odd-chain fatty acids or very long-chain even-chain fatty acids, or salts thereof or derivatives thereof, or mixtures of multiple fatty acids, or salts thereof or derivatives thereof, ranging from about 0.01 mg to about 10,000 mg, about 1 mg to about 5,000 mg, about 5 mg to about 2,000 mg, about 10 mg to about 1,000 mg, or about 50 mg to about 500 mg. A single dose may contain approximately 0.01 mg, 0.1 mg, 1 mg, 5 mg, 10 mg, 20 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, 900 mg, 1000 mg, 2000 mg, 5000 mg, or more of fatty acids, their salts, or derivatives thereof. The dosage can be, for example, about 0.001 mg / kg, about 0.01 mg / kg, about 0.1 mg / kg, about 0.2 mg / kg, about 0.5 mg / kg, about 1 mg / kg, about 2 mg / kg, about 3 mg / kg, about 4 mg / kg, about 5 mg / kg, about 6 mg / kg, about 7 mg / kg, about 8 mg / kg, about 9 mg / kg, about 10 mg / kg, about 15 mg / kg, about 20 mg / kg, about 25 mg / kg, about 30 mg / kg, or more, depending on the body mass of the subject. In some embodiments, the effective amount of C15:0 fatty acid or a pharmaceutically acceptable salt thereof in the pharmaceutical composition is 0.2 to 20 mg / kg body weight. The dosage may be a single dose or a series of two or more doses given over a day or over a period of several days, as appropriate for the individual subject. In some embodiments, the compound is used for a period of continuous therapy, for example, over a period of about one week or more (e.g., one, two, three, four, five, six, seven, eight weeks, or more), several weeks, over a period of about one month or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve months, or more), over a period of about one year or more, or over several years.In some embodiments, fatty acids such as odd-chain fatty acids or very long-chain even-chain fatty acids, or salts thereof or derivatives thereof, may be administered or ingested once, twice, three times, or more times a day.

[0153] As will be understood by those skilled in the art, in certain circumstances, it may be necessary to administer the compounds disclosed herein in amounts exceeding the preferred dosage range described above in order to effectively treat the subject.

[0154] It is also possible to provide unit dosage forms, for example, individual packages containing a pre-measured amount of the composition configured for administration according to a predetermined schedule. Unit dosage forms configured for administration one to three times a day are preferred, but in certain embodiments, it may be desirable to configure unit dosage forms for administration more than three times a day or less than once a day.

[0155] The dosage and dosing interval may be adjusted for individual subjects to provide sufficient plasma levels of the active portion to maintain a predetermined parameter, indicator, or marker value, or minimum effective concentration (MEC). The dosage required to achieve the desired result depends on individual characteristics and administration route. However, serum concentrations can be determined using assays, such as HPLC assays or bioassays.

[0156] In some embodiments, the compounds and methods provided herein are, for example, U.S. Patent No. 7,651,845; U.S. Patent No. 8,251,904; U.S. Patent No. 8,251,904; U.S. Patent No. 4,985,015; U.S. Patent No. 8,827,957; U.S. Patent No. 4,252,159; U.S. Patent No. 5,318,521; U.S. Patent No. 4,718,430; U.S. Patent No. 9,713,600; U.S. Patent No. 9,707,199; U.S. Patent No. 9,687,461; U.S. Patent No. 9,662,306; U.S. Patent Application Publication No. 9,561,206; U.S. Patent Application Publication No. 2011 / 0190702; U.S. Patent Application Publication No. 2017 / 0266144; U.S. Patent Application Publication No. 2016 / 0324814. U.S. Patent Application Publication No. 2016 / 0195559; U.S. Patent Application Publication No. 2016 / 0195558; U.S. Patent Application Publication No. 2016 / 0193172, 2; U.S. Patent Application Publication No. 2016 / 0193171; U.S. Patent Application Publication No. 2016 / 0193170; WO2016 / 111843; DE2615061; and may be used in combination with diagnostic devices, for example, in combination with devices and methods of using devices as described in U.S. Patent Publication No. 2012 / 0072236.

[0157] (Diagnosis and monitoring) This specification provides methods for raising and / or enhancing mood, reducing anxiety and / or pain, treating depression, treating major depressive disorder, or treating seasonal affective disorder.

[0158] In some embodiments, a diagnostic or monitoring method may include the step of measuring the percentage of fatty acids, such as odd-chain fatty acids or very long-chain even-chain fatty acids, in body fluids. In some embodiments, a diagnostic or monitoring method may include the step of measuring markers of a condition provided herein, including a condition associated with mood disorders or pain in a subject. In some embodiments, a diagnostic or monitoring method may include the step of measuring markers of a condition associated with mood disorders or pain. In some embodiments, a correlation between one marker and another may be proven to be beneficial. In some embodiments, a condition associated with mood disorders or pain may be diagnosed by, for example, a threshold level of erythrocyte sedimentation rate, or by referring to serum odd-chain fatty acids or serum very long-chain even-chain fatty acids. In some embodiments, a condition associated with mood disorders or pain provided herein may be diagnosed by referring to a threshold level of a marker of the condition, for example, serum odd-chain fatty acid percentage, serum concentration of odd-chain fatty acids, serum total odd-chain fatty acids, serum very long-chain even-chain fatty acids, serum total very long-chain even-chain fatty acids, or a ratio between two serum fatty acids. For example, a threshold may be determined by referring to a symptom or marker of a condition associated with mood disorders or pain.

[0159] The percentage of fatty acids in the subject, such as odd-chain fatty acids or very long-chain even-chain fatty acids, or markers of conditions associated with mood disorders or pain, can be monitored by any means. Samples for analysis may be derived from any fluid or tissue of the subject, for example, from serum, plasma, red blood cell membranes, urine, and feces. [Examples]

[0160] (Example 1) Compositions comprising pentadecanoic acid and its salts and derivatives, as well as methods for the treatment and prevention of mood disorders and chronic pain, are provided, including compositions and methods for elevating and enhancing mood, reducing anxiety and chronic pain, and treating depression, major depressive disorder, and seasonal affective disorder. Pentadecanoic acid has these activities in humans at daily oral doses ranging from 1 mg / day or less to 200 mg / day or more, for example, 1.0 mg / day to 5.0 mg / day, 5 mg / day to 50 mg / day, 20 mg / day to 200 mg / day, etc., as described herein.

[0161] (method) This study evaluated the potential pharmacological targets of pentadecanoic acid. Specifically, the agonist and antagonist activities of synthetic pentadecanoic acid were investigated across 78 assays using SAFETYscan E / IC50 ELECT (DiscoverX / Eurofins, Fremont, California). In short, various standardized and optimized functional assays were used, including those for pentadecanoate-coupled receptors (ADORA2A, ADRA2A, ADRB1, ADRB2, CB1, CCK1, D2S, ETA, H1, M2, M3, OPRD1, OPRK1, OPRM1, 5HTR1B, 5HTR1B, 5HTR2B, AVPR1A), kinases (LCK, INSR, VEGFR2, ROCK1), transporters (DAT, NET, SERT), ion channels (GABAA, 5-HT3, CA1.2, HERG, KVLQT1 / MINK, NA1.5, NMDAR1 / 2B, NACHR), nuclear receptors (AR, GR), and non-kinase enzymes (COX1, COX2, ACHE, MAOA, PDE3A, PDE4D2). Ten-point concentration curves for both agonist (EC50) and antagonist (IC50) activity were established for each target. Maximum activity (%) was also determined based on comparison with an internal positive control assigned 100% activity. The positive control for both CB1 and CB2 receptor agonist activity was CP 55940 (EC50 = 0.06 nm).

[0162] (result) Pentadecanoic acid exhibited bipartite CB1- and CB2- agonist activity from 2.2 to 20 μM (24.5% agonist activity at CB1=20 μM and 18.2% agonist activity at CB2=20 μM). Figure 1 shows the target CB1 and CB2 agonist activity of pentadecanoic acid at gradually increasing concentrations.

[0163] This study supports the finding that pentadecanoic acid is a dual partial CB1 / CB2 agonist. Based on these activities, pentadecanoic acid may be used in a daily dose to achieve at least 2.2 μM in the body to elevate and / or enhance mood, reduce anxiety and pain, and treat depression, major depressive disorder, and seasonal affective disorder.

[0164] (Example 2) (method) In this study, we evaluated the human cell phenotypic profile of pentadecanoic acid to identify its mechanistic similarities with known active compounds.

[0165] The Diversity PLUS BioMAP panel enables unbiased characterization of test agents across a broad set of systems modeling various human disease states. These systems are designed to model the complex human tissue and disease biology of the vascular system, skin, lungs, and inflammatory tissues. Quantitative measurements of 148 biomarker activities across this broad panel, along with comparative analyses of bioactivity from known bioactive agents, were used to predict and compare the efficacy and function of pentadecanoic acid at eight concentrations ranging from 0.74 to 50 μM.

[0166] Each test drug generated a signature BioMAP profile created from changes in protein biomarker readouts within its individual system environment. Biomarker readouts (7–17 per system) were selected for therapeutic and biological relevance, predicting disease outcomes or specific drug effects, and validated with drugs having known mechanisms of action (MoA). Each readout was quantitatively measured by protein (e.g., ELISA) measuring growth and viability, or by immunoassay-based methods detecting functional assays. BioMAP readouts are diverse and include cell surface receptors, cytokines, chemokines, matrix molecules, and enzymes. Overall, the Diversity PLUS panel contained 148 biomarker readouts capturing biological changes occurring within the physiological context of specific BioMAP systems. Specific BioMAP activities correlate with in vivo biology, and multi-parameter BioMAP profiles have been used to differentiate compounds based on MoA and target selectivity across diverse physiological systems.

[0167] Activated BioMAP systems were incubated with each compound for 24–72 hours. Protein-based biomarkers derived from the activated cell lines were measured and compared to an untreated control system. Biomarker activity was considered "significant" if at least one compound concentration was outside the significant envelope and the effect size was >20% (log10 ratio) >0.1.

[0168] Similarity search analysis was performed to identify top matches between the cell-based phenotypic profile of pentadecanoic acid and other biochemicals in the BioMAP database. The BioMAP database contained over 4,500 reference test agents, including biologics, approved drugs, and experimental compounds. Briefly, Pearson's correlation coefficient (r) was first generated to measure the linear correlation between two profiles based on the similarity of the direction and magnitude of the relationship. Since Pearson's correlation can be influenced by the magnitude of any biomarker activity, a system-by-system weighted average Tanimoto metric was used as a filter to account for underrepresentation of less robust systems. The Tanimoto metric does not consider the amplitude of biomarker activity, but it addresses whether the identity and number of readouts are common on a weighted criterion per system. Annotated profiles were identified as mechanistically similar if r ≥ 0.7 and the readouts of both profiles were outside the range of significant difference with an effect size of 20% or more (|log10 ratio| > 0.1) in the same direction.

[0169] (result) In an unsupervised search of mathematically similar compound profiles from the BioMAP Reference Database, 1.9 μM pentadecanoic acid was similar to CP 55,940 (1.1 μM) (Pearson correlation coefficient, r=0.753), and 20 μM pentadecanoic acid was most similar to bupropione HCl (30 μM) (Pearson correlation coefficient, r=0.823). The Pearson correlation coefficients were above the determined threshold of r=0.7, indicating that pentadecanoic acid has mechanically related similarities to both CP 55,940 and bupropione HCl.

[0170] CP 55,940 is a complete CB1 and CB2 receptor agonist and synthetic cannabinoid that mimics the effects of naturally occurring tetrahydrocannabinol. Bupropion HCl is a norepinephrine-dopamine reuptake inhibitor, or NDRI, approved by the FDA for use as an antidepressant and smoking cessation aid. As seen in Figure 2, the phenotypic profiles of pentadecanoic acid (20 μM) and bupropion HCl are similar.

[0171] In summary, this study demonstrates direct mechanistic similarities between pentadecanoic acid and CB1 / CB2 agonists, as well as NDRI inhibitors, further supporting the use of pentadecanoic acid to achieve a concentration of at least 1.9 uM to enhance and improve mood, reduce anxiety and chronic pain, and treat depression, major depressive disorder, and seasonal affective disorder. [Table 1]

[0172] Figure 2 shows that the top database search result for pentadecanoic acid (20 μM) is bupropion hydrochloride (30 μM). It overlays top similarity matches from a no-reference search of the BioMAP reference database for >4,500 agents using pentadecanoic acid (SRP_ETI-101-AVA). Common biomarker readouts are annotated if the readouts for both profiles are outside the range of significant difference with an effect size >20% (|log10 ratio|>0.1) in the same direction. Similarity search results are filtered and ranked as described in Appendix A. Profiles are identified as having mechanically relevant similarities if their Pearson correlation coefficient is 0.7 or greater.

[0173] (Example 3)

[0174] An odd-chain saturated fatty acid supplement called fatty15®, containing encapsulated pure (>98%) free fatty acid C15:0 powder, was available as a consumer medicine. The recommended dose is a single 100 mg capsule taken orally once daily. Based on this study, which demonstrated C15:0 as a partial CB-1 agonist using a human cell phenotypic profile similar to bupropion, the inventors hypothesized that daily oral C15:0 supplementation would reduce stress and enhance mood.

[0175] Approximately six weeks after receiving the C15:0 supplement "fatty15," customers were given an optional electronic questionnaire to assess short-term effects, which included the following questions: "Overall, to what extent do you agree with the following statement? Since starting to take fatty15, I feel calmer and less stressed" and "Overall, to what extent do you agree with the following statement? Since starting to take, I feel generally happier and / or no longer bothered by things that used to upset me."

[0176] Respondents were asked to choose a number from 1 to 10, where 1 meant strongly disagree and 10 meant strongly agree. A response of 7 or higher was considered to indicate agreement with the statement. They were also asked, "Has fatty15 become a daily health habit?"

[0177] A total of 135 people responded to the 6-week survey. Almost all patients (97%) reported that fatty15 had become part of their daily health management. After 6 weeks of daily oral supplementation of 100 mg of C15:0, 41% of the 135 customers reported feeling calmer and / or less stressed, and 37% reported being generally happier and / or less troubled by what they had been using to upset them.

[0178] These data support the idea that oral supplementation of odd-chain saturated fatty acids, particularly C15:0, at 100 mg / day for 6 weeks can support a calmer, less stressful, and happier mood.

[0179] (Example 2)

[0180] Fatty15™, a nutritional supplement containing encapsulated pure (over 98%) free fatty acid C15:0 powder, is marketed as a consumer health food. The recommended dosage is one 100mg capsule taken orally once daily. Customers were provided with opportunities to share their experiences through voluntary surveys and customer evaluation programs.

[0181] Table 2 summarizes feedback from fatty15™ customers regarding stress and mood. [Table 2]

[0182] These testimonies support the idea that daily oral supplementation of odd-chain saturated fatty acids, specifically 100 mg / day of C15:0, can reduce stress, calm the mind, and improve mood.

[0183] (Example embodiment) Method 1: A method for raising and / or enhancing mood, reducing anxiety and / or pain, treating depression, treating major depressive disorder, or treating seasonal affective disorder, comprising administering to a patient in need of such treatment an effective amount of C15:0 fatty acid or a pharmaceutically acceptable salt thereof in a pharmaceutical composition, dietary supplement, or food.

[0184] Method 2: The method is to administer the substance as a food component, as in Method 1.

[0185] Method 3: The method is to administer the food as a dietary supplement, as in Method 2.

[0186] Method 4: Method 1 for raising and / or enhancing mood.

[0187] Method 5: Method 1 for reducing pain.

[0188] Method 6: Method 1 for reducing anxiety.

[0189] Method 7: Method 1 for treating depression.

[0190] Method 8: Method 1 for treating major depressive disorder.

[0191] Method 9: Method 1 for treating seasonal affective disorder.

[0192] Method 10: One of Methods 1-9, wherein the serum, plasma, or red blood cell membrane concentration of C15:0 fatty acid is increased to a concentration greater than 2.2 μM and less than 30 μM.

[0193] Method 11: C15:0 The fatty acid is pentadecanoic acid, one of methods 1-10.

[0194] Method 12: A C15:0 fatty acid or a pharmaceutically acceptable salt thereof is provided as a pharmaceutical composition in a unit dosage form comprising a C15:0 fatty acid or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, according to any one of Methods 1 to 11.

[0195] Method 13: The unit dosage form contains 0.01 mg to 10,000 mg of C15:0 fatty acid or a pharmaceutically acceptable salt thereof, as in Method 12.

[0196] Method 14: The pharmaceutical composition is substantially free of even-chain saturated fatty acids, according to any one of Methods 12-13.

[0197] Method 15: The pharmaceutical composition is any one of Methods 12-14, which is substantially free of polyunsaturated fatty acids.

[0198] Method 16: C15:0 fatty acids or pharmaceutically acceptable salts thereof are administered to the patient once daily, one of methods 12-15.

[0199] Method 17: The patient is human, and one of Methods 1-16 applies.

[0200] Method 18: The patient is a mammal, one of Methods 1-16.

[0201] Method 19: The patient is livestock, one of Methods 1-16.

[0202] Method 20: The livestock is a dog or a cat, Method 19.

[0203] Method 21: The livestock are cattle, pigs, sheep, goats, horses, turkeys, ducks, or chickens, Method 9.

[0204] Method 22: One of Methods 1-21 is administered to the patient at a dose of 20-200 mg / kg body weight per day of C15:0 fatty acid or a pharmaceutically acceptable salt thereof.

[0205] A composition comprising a 23:C15:0 fatty acid or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, for the purpose of raising and / or enhancing mood, reducing anxiety and / or pain, treating depression, treating major depressive disorder, or treating seasonal affective disorder.

[0206] Composition 24: Composition 23, which is a pharmaceutical composition in unit dosage form.

[0207] Composition 25: Composition 23, which is a nutritional supplement.

[0208] Composition 26: The nutritional supplement is in the form of Composition 23.

[0209] Composition 27: Composition 23, which is a nutritional supplement adapted to be combined with or added to foods, beverages, or other food products.

[0210] Composition 28: A composition which is a food or other food product, as per composition 23.

[0211] Composition 29: Any one of compositions 23-28, or a mood-enhancing and / or enhancing agent.

[0212] Composition 30: Composition 29 for mood enhancement.

[0213] Composition 31: Composition 29 for mood enhancement.

[0214] Composition 32: One of compositions 23-28 for reducing anxiety.

[0215] Composition 33: One of compositions 23 to 28 for reducing pain.

[0216] Composition 34: One of compositions 23 to 28 for the treatment of depression.

[0217] Composition 35: One of compositions 23 to 28 for the treatment of major depressive disorder.

[0218] Composition 36: One of compositions 23 to 28 for the treatment of seasonal affective disorder.

[0219] Any one of compositions 23 to 36, adapted to increase the serum, plasma, or erythrocyte membrane concentration of composition 37:C15:0 fatty acid or a pharmaceutically acceptable salt thereof to a concentration greater than 2.2 μM and less than 30 μM.

[0220] Composition 38:C15:0 The fatty acid or pharmaceutically acceptable salt thereof is pentadecanoic acid, one of compositions 23 to 37.

[0221] Composition 39: Composition 26, wherein the unit dosage form contains 0.01 mg to 10,000 mg of C15:0 fatty acid or a pharmaceutically acceptable salt thereof.

[0222] Composition 40: The pharmaceutical composition is one of compositions 23 to 39, which is substantially free of multi-chain saturated fatty acids.

[0223] Composition 41: The pharmaceutical composition is one of compositions 23 to 40, which is substantially free of polyunsaturated fatty acids.

[0224] Composition 42: A composition comprising any one of compositions 23 to 41, adapted for administering 0.2 to 20 mg / kg body weight per day of C15:0 fatty acids or pharmaceutically acceptable salts thereof to patients in need.

[0225] Composition 43: Composition 26, whose unit dosage form is suitable for administration to a patient once daily.

[0226] Composition 44: The patient is a human, and is one of compositions 23 to 43.

[0227] Composition 45: The patient is a mammal, and is one of compositions 23 to 43.

[0228] Composition 46: The patient is livestock, one of compositions 23 to 43.

[0229] Composition 47: A composition in which the livestock is a dog or a cat.

[0230] Composition 48: A composition in which the domesticated animal is a cow, a pig, a sheep, a goat, a horse, a turkey, a duck, or a chicken.

[0231] Use 49: Use of a composition comprising a C15:0 fatty acid or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier for the purpose of raising and / or enhancing mood, reducing anxiety and / or pain, treating depression, treating major depressive disorder, or treating seasonal affective disorder.

[0232] Use 50: Use 49 to uplift or enhance mood.

[0233] Use 51: Use 50 times to lift your spirits.

[0234] Use 52: 50 uses to improve mood.

[0235] Use 53: Use 49 to reduce anxiety.

[0236] Use 54: Use 49 to relieve pain.

[0237] Use 55: For the treatment of depression, use 49

[0238] Use 56: For the treatment of major depressive disorder, use 49.

[0239] Use 57: For the treatment of seasonal affective disorder, use 49.

[0240] Use 58: The serum, plasma, or red blood cell membrane concentration of C15:0 fatty acid is increased to a concentration greater than 2.2 μM and less than 30 μM, according to any one of Uses 49-57.

[0241] The fatty acid used in 59:C15:0 is pentadecanoic acid, one of the fatty acids used in 49-58.

[0242] Use 60:C15:0 fatty acid or a pharmaceutically acceptable salt thereof is provided as a pharmaceutical composition in a unit dosage form comprising a C15:0 fatty acid or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, one of Uses 49-59.

[0243] Use 61: The unit dosage form contains 0.01 mg to 10,000 mg of C15:0 fatty acid or a pharmaceutically acceptable salt thereof, Use 60.

[0244] Use 62: The pharmaceutical composition is substantially free of even-chain saturated fatty acids, one of Uses 60-61.

[0245] Use 63: The pharmaceutical composition is substantially free of valence unsaturated fatty acids, one of Uses 60-62.

[0246] Use 64:C15:0 fatty acid or a pharmaceutically acceptable salt thereof, one of Uses 60-63, administered to the patient once daily.

[0247] Use 65: The patient is human, one of Uses 49-64.

[0248] Use 66: The patient is a mammal, one of Uses 49-64.

[0249] Use 67: The patient is livestock, one of Uses 49-64.

[0250] Use 68: The livestock is a dog or a cat, use 67.

[0251] Use 69: Livestock are cattle, pigs, sheep, goats, horses, turkeys, ducks, or chickens, Use 67.

[0252] Use 70: 0.2-20 mg / kg body weight of C15:0 fatty acids or pharmaceutically acceptable salts thereof, one of Uses 49-69, to be administered to the patient daily.

[0253] Use 71:C15:0 fatty acids or their pharmaceutically acceptable salts, administered as food components, one of Uses 49-70.

[0254] The above description presents, in full-width, clear, concise, and precise terms, the best mode intended for carrying out the present invention, as well as methods and processes for making and using the present invention, so as to enable those skilled in the art to make and use the present invention. However, the present invention is susceptible to modifications and alternative configurations from the above which are entirely equivalent. Therefore, the present invention is not limited to the specific embodiments disclosed. Rather, the present invention encompasses all modifications and alternative configurations that fall within the spirit and scope of the invention, as generally expressed by the following claims which specifically point to and expressly claim the subject matter of the present invention. Although this disclosure is illustrated and described in detail in the drawings and the above description, such illustrations and descriptions should be considered illustrative or exemplary and not limiting.

[0255] All references cited herein are incorporated herein by reference in their entirety. To the extent that any publications and patents or patent applications incorporated herein conflict with any disclosures contained herein, this specification is intended to take precedence over and / or supersede such conflicting material.

[0256] Unless otherwise defined, all terms (including technical and scientific terms) should be given their ordinary and customary meanings to those skilled in the art, and not limited to any special or customized meanings unless expressly defined herein. Note that the use of certain terms when describing certain features or aspects of the present disclosure should not be construed as implying that the term is redefined herein to include any particular feature of the feature or aspect of the present disclosure to which it relates. Terms and phrases used in this application, and their variations in particular in the appended claims, should be construed as open-ended and not restrictive unless expressly stated otherwise. As such, the term "includes" should be construed as "includes" or "includes, but not limited to," and is synonymous with "includes" or "includes," and does not include any comprehensive or open elements or method steps; the term "has" should be construed as "has at least"; the term "includes" should be construed as "includes"; and the term "includes" should be construed as "includes," but not limited to. The term “example” is used to provide exemplary illustrations of items in discussion; adjectives such as “well-known,” “common,” “standard,” and similar terms should not be interpreted as limiting items to those available for a given period or in the future, but rather as encompassing available known, common, or standard techniques; terms such as “preferred,” “desirable,” “desirable,” or “desirable,” and similar terms should not be understood as meaning that a particular feature is critical, essential, or important to the structure or function of the invention at any point in the present or future, but merely intended to highlight alternative or additional features that may or may not be available in a particular embodiment of the invention; similarly, a group of items linked with “and” should not be interpreted as requiring each and all of those items to be present in the group, but rather as “and / or” unless otherwise explicitly stated.Similarly, a group of items linked with a linked "or" should not be interpreted as requiring mutual exclusivity between the groups, and should be interpreted as "and / or" unless otherwise explicitly stated.

[0257] If a range of values ​​is provided, it is understood that the upper and lower limits, as well as each intermediate value between the upper and lower limits of the range, are included within the embodiment.

[0258] With regard to the use of substantially any plural and / or singular terms herein, those skilled in the art can translate from plural to singular and / or singular to plural as appropriate to the context and / or use. Various singular / plural substitutions may be expressly described herein for clarity. The indefinite article "a" or "an" does not exclude the plural. A single processor or other unit may fulfill the functions of several items enumerated in the claims. The mere fact that certain means are described in different dependent claims does not imply that combinations of these means cannot be used advantageously. No reference numeral in a claim should be construed as limiting in scope.

[0259] It will be further understood by those skilled in the art that if a particular number of introduced claims is intended, such intent is explicitly enumerated in the claims, and if such enumeration is absent, such intent does not exist. For example, to aid understanding, the following appended claims may include the use of the introductory phrases “at least one” and “one or more” to introduce the description of the claims. However, the use of such phrases should not be interpreted as meaning that any particular claim including a reference to a particular claim including such a reference is limited to embodiments including only one such reference, even if the same claim includes the introductory phrase “one or more” or “at least one” and an indefinite article such as “a” or “an” (for example, “a” and / or “an” should typically be interpreted as meaning “at least one” or “one or more”). In addition, even if the specific number of claims introduced is explicitly enumerated, a person skilled in the art will recognize that such enumeration should typically be interpreted to mean at least the number enumerated (for example, "two enumerations" without other modifying factors, typically meaning at least two enumerations, or two or more enumerations). Furthermore, when conventions similar to "at least one of A, B, and C, etc." are used, such constructions will generally be understood by a person skilled in the art (for example, "a system having at least one of A, B, and C" includes, but is not limited to, systems having only A, only B, only C, A and B together, A and C together, B and C together, and / or A, B, and C together, etc.). Where conventions similar to "at least one of A, B, or C" are used, such configurations will generally be understood by those skilled in the art (for example, "a system having at least one of A, B, or C" includes, but is not limited to, systems having only A, only B, only C, together with A and B, together with A and C, together with B and C, and / or together with A, B, and C).It will be further understood by those skilled in the art that substantially any alternative language and / or phrase presenting two or more alternative terms in this specification, claims, or drawings is intended to be understood as construed as including the possibility of including one of the terms, either of the terms, or both of the terms. For example, the term "A or B" is understood to include the possibilities of "A" or "B" or "A and B".

[0260] All numbers used herein to express quantities of components, reaction conditions, etc., should be understood in all cases to be modified by the term “approximately.” Therefore, unless otherwise indicated, the numerical parameters described herein are approximations that may vary depending on the desired properties to be obtained. Each numerical parameter should be interpreted in light of the number of significant figures and common rounding techniques, not as an attempt to limit the application of the doctrine of equivalents to the scope of any claim in any application claiming priority to this application.

[0261] Furthermore, although the above is described in some detail by examples and embodiments for the purpose of clarity and understanding, it will be apparent to those skilled in the art that certain changes and modifications may be made. Accordingly, the description and examples should not be construed as limiting the scope of the invention to the specific embodiments and examples described herein, but rather as encompassing all modifications and substitutions that represent the true scope and spirit of the invention.

Claims

1. A composition for raising and / or enhancing mood, and for reducing anxiety: A composition comprising pentadecanoic acid (C15:0) or a pharmaceutically acceptable salt thereof.

2. The composition according to claim 1, further comprising a pharmaceutically acceptable carrier.

3. The composition according to claim 1, wherein the composition is in unit dosage form.

4. The composition according to claim 1, wherein the composition is in the form of a nutritional supplement.

5. The composition according to claim 4, wherein the nutritional supplement is in a unit dosage form.

6. The composition according to claim 4, wherein the nutritional supplement is in a form adapted to be combined with or added to a food, beverage or other nutritional supplement.

7. The composition is a food component, as described in claim 3.

8. The composition according to claim 1, wherein the serum, plasma, or erythrocyte membrane concentration of C15:0 fatty acid or a pharmaceutically acceptable salt thereof is adapted to increase the concentration to greater than 2.2 μM and less than 30 μM.

9. The composition according to claim 3, wherein the unit dosage form comprises 0.01 mg to 10,000 mg of a C15:0 fatty acid or a pharmaceutically acceptable salt thereof.

10. The composition according to claim 9, wherein the unit dosage form comprises 100 mg to 200 mg of a C15:0 fatty acid or a pharmaceutically acceptable salt thereof.

11. The pharmaceutical composition is the composition according to claim 1, wherein the composition substantially does not contain even-chain saturated fatty acids.

12. The pharmaceutical composition is the composition according to claim 1, wherein the composition substantially does not contain polyunsaturated fatty acids.

13. The pharmaceutical composition is the composition according to any one of claims 1 to 12, which substantially does not contain C17:0 fatty acids.

14. A composition according to any one of claims 1 to 13, comprising 0.2 to 20 mg / kg body weight per day of C15:0 fatty acids or pharmaceutically acceptable salts thereof, adapted for administration to patients in need thereof.

15. The composition according to claim 3, wherein the unit dosage form is suitable for administration to a patient once daily.

16. The composition according to any one of claims 1 to 15, which is formulated for oral administration.

Images